{
    "nctId": "NCT02656589",
    "briefTitle": "microRNA of Human Epidermal Growth Factor Receptor 2 \uff08HER2\uff09Positive Patient Treated With Herceptin",
    "officialTitle": "A Perspective Study of the Predictive Value of microRNA in Patients With HER2 Positive Advanced Stage Breast Cancer Who Were Treated With Herceptin",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "Progress-free survival of patients",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. The patients signed the written informed consent\n2. female patient who is \u2265 18yrs,\n3. HER2 positive: immunohistochemistry (+++) or FISH (+)\n4. stage IV\n5. the patients have no history of chemotherapy ,hormone therapy,radiotherapy or surgery after diagnosis of breast cancer\n6. the result of patients' blood tests are as follow: WBC\u22653.0\u00d7109/L; Plt\u2265100\u00d7109/L;AST/SGOT or ALT/AGPT\u2264tripple of normal upper limit; Creatinine\\<double of the normal upper limit\n7. ECOG scores are 0 or 1 .\n8. The patient is able to take oral pills\n\nExclusion Criteria:\n\n1. The patient was never exposed to herceptin.\n2. The patient suffered from other non-breast malignancy in the last 5 years, except for cervical carcinoma in situ, radical basal cell carcinoma or squamous cell carcinoma.\n3. The life expectancy is less than 3 months.\n4. Severe hepatic function disorder, Child Pugh grade C.\n5. Severe cardiac function disorder, cardiac function is more than grade III;\n6. Prolonged QT interval;\n7. Arrhythmia or taking anti-arrhythmia drugs;\n8. Pregnant or breast feeding female.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}